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Abstract
Background: Atrial fibrillation (AF) occurs in approximately one in three patients after cardiac surgery, and is associated
with increased short-term and long-term mortality, intensive care unit (ICU) and hospital stay, and increased cost of care.
In an attempt to reduce AF incidence in these patients, serum potassium (K+) levels are commonly maintained at the
high end of normal (4.5–5.5 mEq/L). However, such potassium supplementation is without proven benefit, and is not
without negative consequences. It carries clinical risk, negatively impacts patient experience and is both time-consuming
and costly. This protocol describes a randomised controlled pilot trial to assess the feasibility of a proposed randomised
non-inferiority trial to investigate the impact of maintaining serum potassium ≥ 3.6 mEq/L vs ≥ 4.5 mEq/L on the
incidence of new-onset atrial fibrillation in the first 120 hours after isolated elective coronary artery bypass grafting.
Methods: Design: this is a randomized feasibility trial as a pilot for a randomized non-inferiority trial. Participants: are 160
patients undergoing isolated coronary artery bypass grafting at two centres. Allocation: patients will be randomized (1:1)
to protocols aiming to maintain serum potassium at either ≥ 3.6 mEq/L (“relaxed control”) or ≥ 4.5 mEq/L (“tight
control”). Primary analytic aim: was to assess the feasibility and acceptability of planning and delivering the intervention
and trial methods to inform a full-scale non-inferiority trial. Outcome: the primary indicative efficacy outcome measures
being field-tested are feasibility of participant recruitment and randomization, maintaining a protocol violation rate <
10%, and retaining 90% patient follow up 28 days after surgery. The primary clinical outcome measure of the future full
“Tight K Study” will be incidence of AF after cardiac surgery.
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Discussion: The Tight K Pilot will assess the feasibility of conducting the full trial, which is intended to confirm or refute
the efficacy of current potassium management in preventing AF after cardiac surgery.
Trial registration: ClinicalTrials.gov, NCT03195647. Registered on 23 May 2017. Last updated 19June 2017.
Keywords: Potassium, Coronary Artery Bypass Grafting, Atrial Fibrillation, Cardiac Surgery
Background
Approximately one in three patients is affected by atrial
fibrillation (AF) after cardiac surgery, with most episodes
occurring in the first five postoperative days [1–3]. AF
occurrence is associated with increased short-term and
long-term mortality [3–6], intensive care unit (ICU) and
hospital stay [7, 8], and cost of care [9]. Persistence of
this association after adjustment for potential confound-
ing factors suggests that it may be causal [10]. The
incidence and associated costs of AF are expected to in-
crease as the surgical population ages [11].
Potassium plays an important role in cardiac electro-
physiology [12]. Serum concentrations ([K+]) are com-
monly low following cardiac surgery [13], and appear
marginally lower in in non-surgical cohorts among those
suffering atrial arrhythmias [14]. Despite an absence of
proof that this association is causal, efforts to maintain
serum [K+] in the “high-normal” range (4.5–5.5 mEq/L),
as opposed to just intervening if potassium drops below
its lower “normal” threshold, are considered “routine
practice” for AF prevention in patients post-surgery in
many centres across the world [15].
The efficacy of the practice of maintaining high-
normal serum potassium levels remains unproven and
data supporting it are extremely limited, being derived
from observational rather than interventional studies
[15]. Indeed, there are no data to demonstrate that
maintaining a high-normal potassium level is beneficial
in these circumstances, or that aggressive replenishment
of potassium in these patients improves outcome [16].
Meanwhile, potassium supplementation may cause dis-
comfort or harm. Routine central venous potassium ad-
ministration in the early post-operative period, when
oral supplementation is not possible, is time-consuming,
costly, and associated with clinical risk: rapid infusion
can prove fatal [17], and leaving central venous catheters
in situ for the sole purpose of potassium replacement in-
creases infection risk. The annual costs of intravenous
potassium exceed those for other drugs in many cardio-
thoracic units due to the large quantities administered
[18]. Nursing time (e.g. for drug checks and administra-
tion) will also add to this cost. Oral potassium supple-
mentation is commonly associated with gastrointestinal
side effects and is often poorly tolerated by patients [19].
We here describe a trial (Tight K Pilot) designed to as-
sess the feasibility of performing a randomized controlled
non-inferiority trial to assess any impact of targeted main-
tenance of serum K+ concentration ≥ 3.6 mEq/L vs ≥ 4.5
mEq/L on AF incidence after coronary artery bypass graft-
ing (CABG).
Methods/design
The trial is a randomised feasibility trial. This protocol
was written following the Standard Protocol Items:
Recommendations for Interventional trials (SPIRIT)
checklist (see Additional file 1).
Hypothesis for the pilot trial: it will be feasible to recruit
and randomise 160 patients over a period of 6 months,
maintain < 10% protocol violation rate, and retain 90% of
patients for follow up 28 days post-surgery. The protocol
violation rates are defined subsequently (“Endpoints of the
Trial”).
Hypothesis for the main trial: AF will be no more
common (based on a non-inferiority margin of 10%, see
following) after cardiac surgery when serum potassium
levels are maintained at ≥3.6 mEq/L (“relaxed control”)
than when they are maintained at ≥4.5 mEq/L (“tight
control”).
Setting
The Tight K Pilot will be conducted in two UK centres
– the Barts Heart Centre, Barts Health National Health
Service (NHS) Trust and St George’s University
Hospitals NHS Trust, both in London, UK.
Trial population
Eligible patients are those undergoing elective CABG
surgery.
Exclusion criteria
1. Age < 18 years
2. Previous AF
3. Concurrent patient involvement in another clinical
trial assessing post-operative interventions
4. Ongoing infection/sepsis at the time of surgery
5. Pre-operative high-degree atrio-ventricular (AV)
block
6. Pre-operative serum potassium (K+) > 5.5 mEq/L
7. Current or previous use of medication for the
purposes of cardiac rhythm management
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8. Dialysis-dependent end-stage renal failure
9. Unable to give informed consent
Informed consent procedure
Eligible participants will be given a copy of the patient infor-
mation sheet (PIS) at a pre-operative hospital appointment
or upon admission prior to surgery, at which time a
delegated member of the research team will be available to
discuss the trial further and to answer any questions that the
patient may have. Research staff may approach patients prior
to their scheduled hospital appointment via post, telephone
or email to discuss the study.
All participants will be given at least 24 hours to
consider whether or not to take part in the trial. If
willing to take part, they can consent at any time
prior to surgery. Written consent will be obtained on
a consent form.
Randomisation
One hundred and sixty eligible participants with
informed written consent will be allocated in a 1:1 ratio
using an online database (https://sealedenvelope.com/)
to receive either tight (K+ ≥4.5mMol/L) or relaxed (K+
≥3.6mMol/l) potassium control. Patients will be rando-
mised on the day of surgery. The allocation will be
stratified by site.
Trial treatment period
A flowchart of the trial treatment intervention process is
shown in Fig. 1. The trial treatment intervention period
will commence when the patient is admitted to ICU or
any other post-operative care facility after surgery,
according to local practice. It will end 120 hours (5 days)
after that time point, or with occurrence of a clinically
identified episode of AF (see following) - whichever
occurs first.
Fig. 1 Flowchart of the study protocol. CABG, coronary artery bypass grafting; AF atrial fibrillation; post-op, post-operative
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Tight potassium control
Patients randomised to the tight-control group will re-
ceive potassium supplementation if their serum K+ falls
below 4.5 mEq/L (current practice).
Relaxed potassium control
Those randomised to the relaxed-control group will re-
ceive potassium supplementation only if their serum K+
level drops below or equals 3.6 mEq/L.
Potassium supplementation
The administration route used for all potassium replace-
ment will be prescribed according to clinician preference
and given according to existing standardised protocols.
This supplementation may include intravenous (iv) or
oral potassium formulation, administration of
potassium-rich nasogastric feeding regimens or recom-
mending the consumption of potassium-rich foods.
Routine clinical practice
All other clinical practice (including the use of magne-
sium supplementation, the use of beta-blockers or anti-
arrhythmic agents, the route of potassium administra-
tion, and blood tests) will be routine, and independent
of trial allocation. In particular, the frequency with which
serum [K+] is monitored will be according to existing
protocols and clinician/nursing staff preference (Fig. 1).
Patients with AF
In keeping with recognised international criteria, atrial
fibrillation will be defined as an episode of AF lasting ≥
30 seconds that is clinically detected and/or electrocar-
diographically confirmed (on either a 12-lead electrocar-
diogram (ECG) or telemetry) [20]. Routine clinical
monitoring will be supplemented by continuous Holter
monitoring (eMotion Faros 180, Technomed Ltd) for the
first 120 postoperative hours in all participants. Once a
patient has a clinically identified period of AF, the trial
treatment period ends and then there will be no restric-
tion on potassium supplementation and they should be
treated according to current practice (Fig. 1). The sched-
ule of trial enrolment, interventions and assessments is
shown in Fig. 2 (SPIRIT figure).
Endpoints of the trial
The primary outcome measure of this pilot trial is the
performance on feasibility endpoints.
Primary questions for the pilot trial are to investigate:
Fig. 2 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) figure depicting the schedule of enrolment, interventions and
assessment. EQ-5D-5L, 5-level Euroqol-5D questionnaire
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1. Whether it is feasible to recruit 160 patients over a
period of 6 months (20% of those eligible)
2. Whether it is possible to randomise patients into
groups for potassium replacement if K+ <4.5 mEq/L
(usual practice) vs. < 3.6 mEq/L (lower limit of the
normal range)
3. Whether it is feasible for the protocol violation rate
to be no more than 10% (see following)
4. Whether it is feasible to maintain follow-up rates
> 90% at 28 days after CABG
Reasons for a protocol violation may include:
1. A patient from the relaxed-control group being
treated as if they are in the tight-control group or a
patient from the tight-control group being treated as
if they are in the relaxed-control group
2. Failure of randomisation
3. Alteration in planned surgery
4. Failure of the Holter monitoring process
5. Lack of data completion
Secondary endpoints for the pilot trial: in order to fur-
ther inform the proposed main randomised controlled
trial endpoints, the following additional outcomes will
be collected:
1. Incidence and total duration of new-onset AF
arrhythmia post-surgery until day 5. This is the
primary endpoint for the future full Tight K Trial.
2. Mean critical care duration of stay.
3. Mean hospital duration of stay.
4. Incidence and total duration of all other arrhythmias
until day 5 (120 hours), defined using standard
diagnostic criteria.
5. Incidence of in-patient mortality.
6. Incidence of 28-day mortality.
7. Cost-effectiveness.
Holter recordings will be analysed after day 5 by
clinical staff blinded to group allocation. The time of
all clinically identiifed episodes of AF will be docu-
mented and contemporaneous Holter monitoring re-
cordings will be reviewed to confirm or deny the AF
diagnosis after day 5 by clinical staff blinded to treat-
ment allocation. Cardiac arrhythmias that were not
detected clinically will also be documented. A copy of
all Holter reports will be sent to the patient’s primary
admitting surgical team.
Health-related quality of life
All participants will complete a quality of life ques-
tionnaire (5-level Euroqol-5D (EQ-5D-5 L)) prior to
their surgery and also at 28-day follow up, by
telephone or post.
Post-operative follow up at 28 days
Patients surviving to hospital discharge will be followed
up by telephone or post 28 days after randomization, to
determine mortality and further episodes of heart
rhythm problems (if known).
Data collection
The data collected will be utilized to fulfill two distinct
purposes:
1. To assess whether the primary and secondary
endpoints of this study are met.
2. To assess the efficiency of data completion to ensure
protocol compliance. To do this, the same variables
that we intend to collate in the full future study will
be collected in this pilot study.
The following will be collated over the trial study
period (6 months):
 Total number of patients undergoing isolated CABG
 Number of patients screened, invited to participate,
and recruited into the study.
 Patients not followed up at 28 days
 Number of protocol cross-overs and details
– Patients in the relaxed-control group who
inappropriately received potassium
supplementation
– Patients in the tight-control group who
inappropriately did not receive potassium
supplementation
For each protocol violation, a root-cause analysis will
be undertaken that will examine staff roles, timing,
education, and other preventable factors. All patients
will also have a full medical history taken and various
clinical examinations as part of usual care. The following
will be recorded:
 Patient initials
 Ethnic origin
 Cardiac medication and indication (including
beta-blockers, calcium channel blockers,
ACE-inhibitors, angiotensin receptor blockers
(ARBs), aldosterone receptor antagonists,
anticoagulation)
 Medical history: chronic obstructive pulmonary
disease (COPD)/lung disease, diabetes mellitus (and
type), hypertension, myocardial infarction (MI),
chronic kidney disease (CKD), transient ischaemic
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attack (TIA) or stroke/cerebrovascular accident
(CVA), and family history of arrhythmia (and
details)
 Imaging data: left ventricular ejection fraction
(LVEF)/left atrial (LA) size, mitral regurgitation or
stenosis (defined as moderate or worse)
 HAS-BLED and CHADSVASC scores will be
calculated for patients at baseline
For each 24-hour study period (1 through 5), recorded
serum potassium concentrations and potassium adminis-
tration (dose and route) will be documented. Medication
at hospital discharge will be collated, including whether
anticoagulation is commenced for atrial fibrillation.
Duration of stay on ICU, total hospital stay and mortality
will be recorded. Adverse events attributed to K+ replace-
ment, including gastrointestinal symptoms from oral K+
replacement will be collated. Detailed information will be
collected on the resource use associated with delivering
each protocol, including the total number of potassium re-
placement interventions.
Statistical analysis
Power and sample size
One hundred and sixty patients are to be recruited from
two centres, and randomly allocated in a ratio of 1:1. As
this is a pilot trial to assess feasibility, power calculations
are not appropriate. If the anticipated recruitment,
follow-up and retention rates are demonstrated over a 6-
month recruitment period, this would confirm the feasi-
bility of a multicentre randomised controlled non-
inferiority trial in 1682 patients with an estimated eli-
gible cohort of 8700 patients over 3.5 years.
The sample size calculation for the main trial is based
on a baseline incidence of AF of 35% [1, 21]; a clinically
relevant non-inferiority margin of 10%; a true difference
in favour of tight potassium control of 2%, 90% power; a
one-sided alpha of 2.5% (equivalent to a two-sided alpha
of 5%) and < 10% protocol violations. Due to this antici-
pated protocol violation rate, a greater number of pa-
tients will be recruited to the full study, as not all will be
included in the final analysis.
Outcome analyses
The primary outcome measure of this pilot trial will be
feasibility in terms of numbers recruited and rando-
mised, protocol fidelity, and follow-up rates by trial arm.
These statistics will inform a “Consolidated Standards of
Reporting Trials” (CONSORT) diagram reporting re-
cruitment, treatment, and retention.
Additionally descriptive summaries of baseline and
follow-up data by arm will be tabulated. No significance
tests will be performed to test for differences at baseline,
or given that this is a pilot trial, at follow up. Descriptive
statistics for continuous variables will include the mean,
standard deviation, median, range, and the number of
observations. Categorical variables will be presented as
numbers and percentages. Exploratory analysis of the
main trial outcomes will be by intention to treat (ITT)
and given the non-inferiority trial design for the main
trial, a per-protocol analysis will also be considered [22].
As this is a pilot trial, no interpretation will be made of
any effect sizes and findings will primarily be used to
help refine the design of the main trial. This will include
assessment of rates of missing data. No formal analysis
to account for missing data will be undertaken in this
pilot trial. A detailed cost-effectiveness analysis will not
be undertaken in this pilot trial, but simple analyses of
cost-effectiveness will be performed utilizing data relat-
ing to data on quality of life and length of stay. Statistical
analysis will be carried out blinded to treatment
allocation.
Ethical issues
The trial has been reviewed and ethically approved by
the National Research Ethics Service London Committee
– Camden and Kings Cross. The REC number is LO/17/
0318. The trial will conform to the spirit and the letter
of the declaration of Helsinki, and will be in accordance
with the Barts Health NHS Trust and London School of
Hygiene & Tropical Medicine (LSHTM) Good Clinical
Practice (GCP) guidelines. The trial will be carried
out in accordance with the ethical principles in the
Research Governance Framework for Health and
Social Care, Second Edition, 2005 and its subsequent
amendments as applicable and applicable legal and
regulatory requirements.
Confidentiality: participant data will be kept confiden-
tial and managed in accordance with the Data Protection
Act, NHS Caldecott principles, The Research Govern-
ance Framework for Health and Social Care, and the
conditions of Research Ethics Committee Approval.
Withdrawal of participants: a patient may decide to
withdraw from the trial at any time without prejudice to
their future care and will undergo standard clinical care.
Patients will be encouraged to allow data and samples
that have been collected before withdrawal to be used in
the analyses. However, if consent to use data is also
withdrawn, then these will be discarded. Patients with-
drawing from the trial will continue to be followed up
by their local clinical team. There should be no need for
further follow up from the research team. The Clinical
Trials Unit at LSHTM should be informed by email if a
patient has withdrawn from the trial. A withdrawal form
will be completed on the trial electronic case report
form.
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Safety reporting: Barts NHS Trust, as Sponsor of
this trial, has responsibility to ensure arrangements
are in place to record, notify, assess, report, analyse,
and manage adverse events in order to comply with
the UK regulations of Medicines for Human Use
(Clinical Trials) Regulations 2004. All sites involved
in the trial are expected to inform the Chief Investi-
gator of any serious adverse events/reactions within
24 hours so that appropriate safety reporting proce-
dures can be followed by the Sponsor.
All adverse events judged by either the investigator
or the Sponsor as having a reasonable suspected
causal relationship with potassium supplementation
qualify as adverse reactions. Whilst any suspected,
unexpected, serious adverse reaction (SUSAR) involv-
ing potassium will be reported according to the time-
lines for SUSARs, expected side effects of potassium
will be reported in the end-of-trial safety report un-
less serious enough to warrant expedited reporting.
Trial governance
Trial documentation: relevant trial documentation will
be kept for a minimum of 15 years. Electronic data
will be stored in a fully audited data centre in the
UK with appropriate certifications including ISO
27001:2005 (Information Security) and 9001:2008
(Quality Management).
Trial registration and conduct: the trial is registered
with ClinicalTrials.gov, identifier: NCT03195647. We
will follow the Medical Research Council Guidelines on
GCP in Clinical Trials. All investigators have been
trained in GCP.
The Sponsor is Barts Health NHS Trust.
Trial Steering Committee (TSC): the trial will be over-
seen by the TSC, including an independent chair and at
least two other independent members. The TSC will
meet periodically during the trial.
Data Safety and Monitoring Committee (DSMC):
the DSMC will be independent of the investigators
and of the TSC, but will report to the TSC and (via
the TSC to the Sponsor). The DSMC will consist of
an independent chair, a senior statistician and at least
one other senior clinician independent of the investi-
gators. The DSMC will meet prior to the start of the
trial and as this is a pilot trial their main role will be
to monitor safety on an ongoing basis. They will also
monitor data for quality and completeness. This will
be facilitated through the development of a trial-
specific database and an adverse-event database.
Trial management: the trial will be directed by the
chief investigator and a project management group
which will include the trial manager, data manager
and trial statistician.
Discussion
Disappointingly little progress has been made in effect-
ively preventing AF after cardiac surgery [23]. Practice is
diverse, and the supporting evidence base is weak [9].
Anecdotally, the commonest practice is to maintain
serum [K+] in the high-normal range. The evidence base
underpinning such practice is limited. Whilst postopera-
tive potassium supplementation has been associated with
reduced AF risk after CBP [2], such data are retrospect-
ive and no specific potassium target is suggested.
We have opted to address the efficacy of this practice
in participants undergoing open CBP - a group that
represents a large proportion of the total cardiac surgical
workload. By choosing a large and comparatively
homogenous patient cohort, the feasibility of delivering
this study should be maximized.
A study that aims to conclusively assess the effective-
ness of an established practice requires a non-inferiority,
individually randomised design. In our case, that will
require large patient numbers. It was felt important by
both investigators and funders to perform a feasibility
study before embarking on a large-scale trial in order to
determine possible barriers to successfully implementing
a seemingly simple protocol such as ours.
The investigators felt that it was important that any
such study should be pragmatic and reflect “real-world”
practice as far as possible. Therefore, minimal restric-
tions have been placed on the management of partici-
pants following surgery. Specifically, use of magnesium
supplementation or antiarrhythmic drugs is unrestricted.
The true incidence of AF following cardiac surgery is
controversial with a range of AF incidence reported in
the literature, ranging from 10 to 65% [1]. The consen-
sus from our Protocol Development Group was that our
chosen non-inferiority margin of 10% is reasonable and
pragmatic. Opting to utilize a smaller non-inferiority
margin may make the future full study unviable, due to
a significant increase in sample size and costs.
The findings of the future full study are intended to
make a significant contribution to optimization of care
for cardiac surgical participants. If effective, potassium
supplementation to a high target level could be imple-
mented as a standard of care, and costs related to peri-
operative morbidity reduced. If potassium supplement is
shown to have no benefit, the costs and risks of adminis-
tration of potassium supplement that are avoided could
be substantial.
Trial status
The trial is currently being set up at two sites.
Recruitment is scheduled to start at the first site by 1
August 2017. The proposed start date is 1 August
2017. The proposed end date is 28 February 2017
(end of follow up).
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